Deutsche Bank AG Makes New $3.49 Million Investment in Summit Therapeutics PLC $SMMT

Deutsche Bank AG acquired a new stake in shares of Summit Therapeutics PLC (NASDAQ:SMMT) in the 2nd quarter, HoldingsChannel reports. The fund acquired 239,347 shares of the company’s stock, valued at approximately $3,487,000.

A number of other institutional investors also recently modified their holdings of SMMT. Ball & Co Wealth Management Inc. purchased a new stake in Summit Therapeutics in the first quarter worth $28,000. Kestra Advisory Services LLC bought a new stake in shares of Summit Therapeutics during the 4th quarter valued at $28,000. Parallel Advisors LLC purchased a new stake in shares of Summit Therapeutics in the 3rd quarter worth about $39,000. T. Rowe Price Investment Management Inc. grew its position in shares of Summit Therapeutics by 2,654.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,873 shares of the company’s stock worth $33,000 after buying an additional 1,805 shares during the period. Finally, Truvestments Capital LLC increased its stake in shares of Summit Therapeutics by 200.2% in the 4th quarter. Truvestments Capital LLC now owns 2,603 shares of the company’s stock worth $46,000 after acquiring an additional 1,736 shares in the last quarter. 4.61% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on SMMT shares. Leerink Partners upgraded Summit Therapeutics from an “underperform” rating to a “market perform” rating and upped their price target for the stock from $12.00 to $13.00 in a research note on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Summit Therapeutics in a research note on Friday, July 17th. Wall Street Zen lowered Summit Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. HC Wainwright reiterated a “neutral” rating on shares of Summit Therapeutics in a research note on Wednesday. Finally, Piper Sandler cut their price objective on shares of Summit Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $24.07.

Summit Therapeutics Stock Performance

Summit Therapeutics stock opened at $14.23 on Thursday. Summit Therapeutics PLC has a one year low of $12.07 and a one year high of $29.23. The stock has a fifty day moving average of $14.11 and a 200 day moving average of $16.18. The stock has a market cap of $11.35 billion, a PE ratio of -12.71 and a beta of -1.23.

Summit Therapeutics (NASDAQ:SMMT) last released its quarterly earnings results on Thursday, July 23rd. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.01). As a group, sell-side analysts predict that Summit Therapeutics PLC will post -1.2 EPS for the current fiscal year.

Key Stories Impacting Summit Therapeutics

Here are the key news stories impacting Summit Therapeutics this week:

• Positive Sentiment: Partner Akeso reported positive topline results from the Phase 3 HARMONi-GI1 trial in advanced biliary tract cancer. Ivonescimab plus chemotherapy delivered a statistically significant overall-survival benefit versus durvalumab plus chemotherapy, potentially strengthening the drug’s commercial opportunity beyond non-small-cell lung cancer. HARMONi-GI1 biliary tract cancer results
• Positive Sentiment: The HARMONi-GI1 findings were described as outperforming AstraZeneca’s Imfinzi, raising expectations for ivonescimab’s competitive positioning in gastrointestinal cancers. Ivonescimab outperforms Imfinzi
• Positive Sentiment: Results from the global Phase 3 HARMONi trial, published in The Lancet Oncology, showed a statistically significant and clinically meaningful progression-free-survival improvement for ivonescimab plus chemotherapy in EGFR-mutated non-small-cell lung cancer. This adds peer-reviewed support for Summit’s lead program while investors await pivotal global data and potential FDA decisions. Global HARMONi trial publication
• Positive Sentiment: Seeking Alpha upgraded Summit to Buy, citing improving sentiment and approaching clinical and regulatory catalysts. The upgrade may be contributing to greater buying interest despite the stock’s high volatility. Summit Therapeutics rating upgrade
• Neutral Sentiment: HC Wainwright reaffirmed a Neutral rating, indicating that some analysts remain cautious while awaiting additional efficacy, regulatory, and commercial evidence.
• Negative Sentiment: Summit’s cash may cover only four to five quarters, while aggressive pipeline expansion and elevated operating expenses increase cash-burn and going-concern risks. The company also recently reported a quarterly loss slightly wider than analysts expected.

Insider Buying and Selling

In other news, CFO Manmeet Singh Soni bought 50,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was bought at an average price of $14.45 per share, with a total value of $722,500.00. Following the acquisition, the chief financial officer owned 3,123,603 shares of the company’s stock, valued at approximately $45,136,063.35. This represents a 1.63% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Mahkam Zanganeh bought 3,810,000 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The shares were acquired at an average price of $13.12 per share, with a total value of $49,987,200.00. Following the transaction, the chief executive officer directly owned 573,883,879 shares of the company’s stock, valued at $7,529,356,492.48. This represents a 0.67% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders bought 7,870,000 shares of company stock valued at $103,616,900. 83.50% of the stock is owned by corporate insiders.

Summit Therapeutics Profile

Summit Therapeutics plc is a clinical?stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life?threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.